Fast TILs

Fast TILs is an investigational autologous adoptive cellular therapy (ACT) developed by the Allegheny Health Network Research Institute (Allegheny Singer Research Institute). The therapy utilizes pleural infiltrating T-cells (PITs) harvested directly from a patient's malignant pleural effusion. These cells are rapidly expanded and activated ex vivo using CD3/CD28 microparticles to create a therapeutic product. The treatment protocol involves lymphodepleting chemotherapy followed by the intrapleural administration of the expanded PITs via an indwelling catheter. To support the survival and anti-tumor activity of the infused cells, low-dose Interleukin-2 (IL-2) is also administered intrapleurally. This approach is specifically designed to treat cancers involving the pleural space, such as malignant mesothelioma and metastatic pleural effusions from various epithelial primary tumors.

Other names

autologous pleural infiltrating T-cellspleural infiltrating T-cellsPITsFast TILlocally manufactured adoptive cellular therapy product